Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas

Neuro-Oncology

Volumn 16, Issue 10, 2014, Pages 1408-1416

  Karajannis, Matthias A ^a   Legault, Geneviève ^a   Fisher, Michael J ^b   Milla, Sarah S ^c   Cohen, Kenneth J ^d   Wisoff, Jeffrey H ^c   Harter, David H ^c   Goldberg, Judith D ^c   Hochman, Tsivia ^b   Merkelson, Amanda ^a   Bloom, Michael C ^c   Sievert, Angela J ^b   Resnick, Adam C ^b   Dhall, Girish ^e   Jones, David T W ^f   Korshunov, Andrey ^f   Pfister, Stefan M ^f   Eberhart, Charles G ^g   Zagzag, David ^c   Allen, Jeffrey C ^a  

^a NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Low grade glioma; Pediatric low grade astrocytoma; Phase II trial; Sorafenib

Indexed keywords

B RAF KINASE; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ALOPECIA; ANOREXIA; ARTICLE; ASTROCYTOMA; CANCER FATIGUE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROFIBROMATOSIS TYPE 1; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL MUCOSITIS; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SCHOOL CHILD; SURVIVAL RATE; VOLUMETRY; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CLINICAL TRIAL; DRUG EFFECTS; KAPLAN MEIER METHOD; MORTALITY; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADOLESCENT; ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD, PRESCHOOL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MAP KINASE SIGNALING SYSTEM; MICE; NIACINAMIDE; NIH 3T3 CELLS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84921596103     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou059     Document Type: Article

References (34)

1. Qaddoumi I, Sultan I, Broniscer A. Pediatric low-grade gliomas and the need for newoptions for therapy: Why and how?. Cancer Biol Ther. 2009;8(1):1-7.
2. Albers AC, Gutmann DH. Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother. 2009;9(4):535-539.
3. Nakamura M, Shimada K, Ishida E, et al. Molecular pathogenesis of pediatric astrocytic tumors. Neuro Oncol. 2007;9(2):113-123.
4. Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602-612.
5. Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45(8):927-932.
6. Hatva E, Kaipainen A, Mentula P, et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol. 1995;146(2):368-378.
7. Bartels U, Hawkins C, Jing M, et al. Vascularity and angiogenesis as predictors of growth in optic pathway/hypothalamic gliomas. J Neurosurg. 2006;104(5 Suppl):314-320.
8. Guha A, Dashner K, Black PM, et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. Int J Cancer. 1995;60(2):168-173.
9. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52(7):791-795.
10. Hwang EI, Jakacki RI, Fisher MJ, et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer. 2013;60(5):776-782.
11. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-867.
12. Gronych J, Korshunov A, Bageritz J, et al. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. J Clin Invest. 2011;121(4):1344-1348.
13. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109.
14. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59(5):561-574.
15. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008;7(4):496-501.
16. Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012;18(21):6011-6022.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. 1989;10(1):1-10.
18. Kim A, Dombi E, Tepas K, et al. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer. 2013;60(3):396-401.
19. Robert C, Mateus C, Spatz A, et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol. 2009;60(2):299-305.
20. Korshunov A, Meyer J, Capper D, et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 2009;118(3):401-405.
21. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122(1):11-19.
22. Lin A, Rodriguez FJ, Karajannis MA, et al. BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol. 2012;71(1):66-72.
23. Sievert AJ, Lang SS, Boucher KL, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A. 2013;110(15):5957-5962.
24. Gajjar A, Sanford RA, Heideman R, et al. Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. J Clin Oncol. 1997;15(8):2792-2799.
25. Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(21):2641-2647.
26. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358-1363.
27. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007;110(7):1542-1550.
28. Botton T, Yeh I, Nelson T, et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res. 2013;26(6):845-851.
29. Spirli C, Morell CM, Locatelli L, et al. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology. 2012;56(6):2363-2374.
30. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
31. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
32. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
33. Wu J, Dombi E, Jousma E, et al. Preclincial testing of sorafenib and RAD001 in the Nf (flox/flox);DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer. 2012;58(2):173-180.
34. Hatzivassiliou G, Haling JR, Chen H, et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers. Nature. 2013;501(7466):232-236.